tiprankstipranks
Advertisement

IWO - ETF AI Analysis

Compare

Top Page

IWO

iShares Russell 2000 Growth ETF (IWO)

Rating:62Neutral
Price Target:
IWO, the iShares Russell 2000 Growth ETF, has a solid overall rating that reflects a mix of strong growth stories and some higher-risk names. Standout holdings like Krystal Biotech, Argan, and JFrog support the fund’s quality with robust financial performance, positive earnings updates, and growth-focused strategies, while companies such as Cipher Mining and other firms with high valuations or ongoing losses introduce more risk and help explain why the rating is not higher. The main risk factor is the ETF’s focus on smaller growth companies, which often come with profitability challenges, richer valuations, and more volatile price swings.
Positive Factors
Strong Top Holdings
Many of the largest positions have shown strong gains this year, helping support the ETF’s overall performance.
Sector Diversification Across Growth Areas
The fund spreads its assets across several growth-oriented sectors like health care, technology, and industrials, which helps reduce reliance on any single industry.
Moderate Expense Ratio for a Specialized Fund
The ETF’s expense ratio is reasonable for a small-cap growth strategy, allowing investors to access a focused segment of the market without very high ongoing costs.
Negative Factors
Heavy Tilt Toward Health Care and Technology
A large share of the portfolio is concentrated in health care and technology stocks, which can make returns more sensitive to swings in these sectors.
Almost Entirely U.S.-Focused
With nearly all assets invested in U.S. companies, the fund offers little geographic diversification and is highly exposed to the U.S. economy.
Short-Term Volatility in Recent Performance
The recent one-month performance has been weak, suggesting that investors should be prepared for short-term ups and downs in this small-cap growth ETF.

IWO vs. SPDR S&P 500 ETF (SPY)

IWO Summary

The iShares Russell 2000 Growth ETF (IWO) invests in small U.S. companies that are expected to grow quickly, following the Russell 2000 Growth Index. It holds many younger, fast-growing businesses across areas like health care and technology, including names such as JFrog and Brinker International. Someone might invest in IWO to seek higher long-term growth and to diversify beyond large, well-known companies by owning a wide basket of smaller firms. However, because it focuses on small growth stocks, its price can be more volatile and can go up and down sharply with changes in the stock market.
How much will it cost me?The iShares Russell 2000 Growth ETF (IWO) has an expense ratio of 0.24%, which means you’ll pay $2.40 per year for every $1,000 invested. This is slightly higher than average for ETFs because it tracks a small-cap growth index, which requires more active management compared to broad market or large-cap passive funds.
What would affect this ETF?The iShares Russell 2000 Growth ETF (IWO) could benefit from advancements in technology and healthcare, as these sectors make up a significant portion of its holdings and are often driven by innovation and demand for new solutions. However, small-cap growth stocks are sensitive to rising interest rates and economic slowdowns, which could negatively impact their ability to secure funding and sustain growth. Additionally, regulatory changes or geopolitical tensions affecting U.S.-based companies may pose risks to the ETF's performance.

IWO Top 10 Holdings

IWO is leaning hard into U.S. small-cap health care and tech, with names like Crinetics Pharmaceuticals and BrightSpring Health Services doing much of the heavy lifting as their shares keep rising on upbeat drug and services stories. Glaukos and Protagonist Therapeutics add to the health care tilt, contributing steady-to-strong gains but with valuations that look a bit stretched. On the tech side, JFrog has been a rocket over the past few months, though recent weakness hints at some turbulence. Overall, performance is being driven by a concentrated bet on innovative, domestically focused growth names.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Moog0.76%$110.25M$13.22B103.78%
73
Outperform
BrightSpring Health Services, Inc.0.76%$109.10M$14.30B204.02%
67
Neutral
Glaukos0.62%$89.04M$9.94B93.50%
61
Neutral
Krystal Biotech0.61%$87.92M$10.81B117.30%
80
Outperform
Brinker International0.58%$83.68M$9.00B37.07%
70
Neutral
Crinetics Pharmaceuticals0.55%$79.45M$8.86B200.00%
61
Neutral
Healthequity0.55%$78.69M$8.44B10.49%
76
Outperform
JFrog0.54%$78.51M$9.50B90.34%
73
Outperform
Protagonist Therapeutics0.54%$78.13M$8.92B153.84%
68
Neutral
StoneX Group0.54%$77.95M$9.23B77.68%
58
Neutral

IWO Technical Analysis

Technical Analysis Sentiment
Negative
Last Price
Price Trends
50DMA
379.57
Negative
100DMA
359.86
Positive
200DMA
345.19
Positive
Market Momentum
MACD
RSI
STOCH
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IWO, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 377.92, equal to the 50-day MA of 379.57, and equal to the 200-day MA of 345.19, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IWO.

IWO Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$14.40B0.24%
62
Neutral
$109.72B0.06%
65
Neutral
$80.50B0.19%
62
Neutral
$79.15B0.03%
66
Neutral
$22.81B0.05%
65
Neutral
$1.45B0.06%
60
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IWO
iShares Russell 2000 Growth ETF
370.67
80.45
27.72%
IJR
iShares Core S&P Small Cap ETF
IWM
iShares Russell 2000 ETF
VB
Vanguard Small-Cap ETF
VBK
Vanguard Small-Cap Growth ETF
VTWG
Vanguard Russell 2000 Growth ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement